Skip to content
value.today

Kamada Ltd.

KMDA
$463 Mmarket cap on Aug 1, 2026+73.3% since Jan 2024
Compare
World rank
#12,881
Revenue
$180 M
For year ending December-2025
Net income
$20 M
11.2% margin
SEC filing
Employees
393
As of December 31, 2025
SEC filing

Kamada Ltd. in brief

Kamada Ltd. is a listed company in the Pharmaceutical industry, based in Israel. It was founded in 1990. Its market value was $463 M on 1 August 2026, which makes it the 12,881st largest listed company in the world and the 142nd largest in Israel on this site. In the year to December 2025 it had sales of $180 M and a net profit of $20 M, about 11 cents of profit for every dollar of sales. It employs about 393 people and Amir London is its chief executive. Its largest product and service lines by sales in 2025 were Proprietary Products (87%) and Distribution (13%). By market, the largest shares of its 2025 sales came from U.S.A (55%), Israel (16%) and Latin America (13%). Its shares trade under the symbol KMDA (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Kamada Ltd.

Under the Israeli Economic Competition Law, 5758-1988, as amended, a company that supplies or acquires more than 50% of any product or service in Israel in a relevant market may be deemed to be a monopoly. In addition, any company that has “significant market power” (within the meaning of the Competition Law), even if it does not hold market share that is greater than 50%, shall be deemed to be a monopolist under the Competition Law. A monopolist is prohibited from participating in certain business practices, including unreasonably refusing to sell products or provide services over which a monopoly exists, charging unfair prices for such products or services, and abusing its position in the market in a manner that might reduce business competition or harm the public. In addition, the General Director of the Israeli Competition Authority may determine that a company is a monopoly and has the right to order such company to change its conduct in matters that may adversely affect business competition or the public, including by imposing restrictions on its conduct. Depending on the analysis and the definition of the different products we distribute in the markets in which we operate, we may be deemed to be a “monopoly” under the Competition Law with respect to certain of our products. Furthermore, following an amendment to the Competition Law that became effective in August 2015, which repealed the statutory exemption that existed under the Competition Law for restrictive arrangements that were mutually exclusive arrangements, we may face difficulties in certain cases negotiating distribution agreements with foreign pharmaceutical manufacturers.

From the company's annual report filed with the US SEC: read the report

Kamada Ltd. timeline

3 events, 1990–2013
  1. 1990
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 31 May 2013; shares registered for exchange trading on 28 May 2013.

Events of Kamada Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$137 M$275 M$412 M$550 M2020202120222023202420252026

World rank over time

▲ up 1,632 places since 2020
2020-01-01: #14199#14,19920202021-01-01: #13900#13,90020212022-01-07: #16794#16,79420222022-12-25: #18721#18,72120222023-07-30: #17510#17,51020232024-01-05: #16408#16,40820242026-03-08: #6954#6,95420262026-08-01: #12567#12,5672026

Rank in Israel: #128 (Jan 2020) · #135 (Jan 2021) · #201 (Jan 2022) · #194 (Dec 2022) · #180 (Jul 2023) · #164 (Jan 2024) · #20 (Mar 2026) · #143 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
22.9×
Price / sales (TTM)
2.6×
Price / book
1.7×
Free cash flow yield
3.4%
Net margin (TTM)
11.2%
Operating margin
14.5%
Return on equity
7.5%
Liabilities / assets
29.0%
Net debt
$-17M
Revenue growth
+12.1%
R&D / revenue
7.2%
Revenue per employee
$459 K
Profit per employee
$51 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $114M, net income $22M$114MFY18Fiscal year ending Dec 2019: revenue $127M, net income $22M$127MFY19Fiscal year ending Dec 2020: revenue $133M, net income $17M$133MFY20Fiscal year ending Dec 2021: revenue $104M, net income $-2M$104MFY21Fiscal year ending Dec 2022: revenue $129M, net income $-2M$129MFY22Fiscal year ending Dec 2023: revenue $143M, net income $8M$143MFY23Fiscal year ending Dec 2024: revenue $161M, net income $14M$161MFY24Fiscal year ending Dec 2025: revenue $180M, net income $20M$180MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$180M+12.1%$26M$20M11.2%
Dec 2024$161M+12.9%$20M$14M9.0%
Dec 2023$143M+10.2%$10M$8M5.8%
Dec 2022$129M+24.8%$5M$-2M-1.8%
Dec 2021$104M-22.2%$-1M$-2M-2.2%
Dec 2020$133M+4.8%$19M$17M12.9%
Dec 2019$127M+11.1%$23M$22M17.5%
Dec 2018$114M—$19M$22M19.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$25M$10M$16M$0.35—
Dec 2024$48M$11M$37M$0.25—
Dec 2023$4M$6M$-2M$0.15—
Dec 2022$29M$4M$25M$-0.05—
Dec 2021$-9M$4M$-13M$-0.05—
Dec 2020$19M$5M$14M$0.38—
Dec 2019$28M$2M$25M$0.55—
Dec 2018$11M$3M$8M$0.55—

SEC filings

Official filings of Kamada Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$180 M
Operating income
$26 M
Net income
$20 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$379 M
Total liabilities
$110 M
Total equity
$269 M

As of December-2025

Top 60 institutional investors in Kamada Ltd.#

As of Sep 30, 2026
60 institutions held 7.0 M shares on Sep 30, 2026. Filings read through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Kamada Ltd.
#InstitutionShares heldChange (shares)ValueFiled
1Phoenix Financial Ltd.1,649,734-5,218 (-0.32%)$14 MNov 9, 2026
2Renaissance Technologies LLC819,605+77,187 (+10.40%)$7 MNov 12, 2026
3Wells Fargo & Company/mn595,563+3,499 (+0.59%)$5 MNov 16, 2026
4Arrowstreet Capital, Limited Partnership571,249New$5 MNov 13, 2026
5Acadian Asset Management LLC450,593+296,218 (+191.88%)$4 MNov 9, 2026
6Goldman Sachs Group Inc399,299+340,253 (+576.25%)$3 MNov 16, 2026
7Dimensional Fund Advisors LP330,405+28,725 (+9.52%)$3 MNov 4, 2026
8Two Sigma Investments, LP277,313+126,213 (+83.53%)$2 MNov 16, 2026
9Bank Of America Corp /de/204,881New$2 MNov 16, 2026
10Marshall Wace, LLP188,037+112,855 (+150.11%)$2 MNov 13, 2026
11Huntleigh Advisors, Inc.168,072+5,428 (+3.34%)$1 MNov 3, 2026
12Renaissance Group LLC150,164+25,268 (+20.23%)$1 MNov 12, 2026
13Envestnet Asset Management Inc122,048+67,379 (+123.25%)$1 MNov 16, 2026
14Jane Street Group, LLC102,845+81,537 (+382.66%)$1 MNov 12, 2026
15Millennium Management LLC97,562+68,356 (+234.05%)$1 MNov 16, 2026
16Quadrature Capital Ltd78,654+44,404 (+129.65%)$1 MNov 13, 2026
17UBS Group AG70,420+64,845 (+1163.14%)$1 MNov 10, 2026
18Stifel Financial Corp68,524+30,125 (+78.45%)$1 MNov 12, 2026
19Man Group plc65,703+3,814 (+6.16%)$1 MNov 16, 2026
20BlackRock, Inc.49,050+3,676 (+8.10%)$0 MNov 13, 2026
21LSV Asset Management47,8000 (0.00%)$0 MNov 6, 2026
22Aristides Capital LLC44,359+8,328 (+23.11%)$0 MNov 16, 2026
23Barclays PLC43,882+32,495 (+285.37%)$0 MNov 6, 2026
24XTX Topco Ltd34,765+3,415 (+10.89%)$0 MNov 16, 2026
25Geode Capital Management, LLC33,113-4,390 (-11.71%)$0 MNov 6, 2026

All 60 institutional investors: 26 to 60, with who bought and sold →

Mutual funds holding Kamada Ltd.#

25 funds hold shares worth $5 M (about 1.0% of the company). Since their previous reports 9 added shares and 2 sold, selling $2 M net.
Mutual funds holding Kamada Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP203,071$1 M0.32%0.02%no changeJul 31, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP98,548$1 M0.15%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP60,576$0 M0.09%<0.01%+26%Jul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP53,547$0 M0.08%<0.01%+41%Jul 31, 2026
🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP45,903$0 M0.07%<0.01%+70%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC37,503$0 M0.06%<0.01%+28%May 31, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP28,075$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP20,160$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Siit World Equity Ex-Us FundSEI INVESTMENTS MANAGEMENT CORPORATION12,431$0 M0.02%<0.01%−23%May 31, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP9,872$0 M0.02%<0.01%+35%Jul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP8,915$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP8,369$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP7,363$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP6,066$0 M<0.01%<0.01%+29%Jul 31, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC5,054$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors4,670$0 M<0.01%<0.01%+2.1%Jul 31, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP4,386$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust3,649$0 M<0.01%<0.01%+19%May 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP3,545$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC1,616$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP1,450$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC700$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation634$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust543$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Avantis International Equity FundAmerican Century ETF Trust160$0 M<0.01%<0.01%no changeMay 31, 2026

As of Jul 31, 2026

Insider trading at Kamada Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
0
0 purchases, 0 insiders
Sold, 12 months
1.7 M
4 sales, 1 insider
Net, 12 months
-1.7 M
open market only
Insiders on file
3
since
Kamada Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Yael BrennerVP QualityOption exercise+5,0005.93030 Klocal11,266Form 4
filed Nir LivnehVP, General CounselOption exercise+10,0005.37054 Klocal10,000Form 4
filed David TsurDirectorSell-22,8278.180187 Klocal407,929Form 4
filed Yael BrennerVP QualityShares withheld for tax-1,3718.36011 Klocal6,266Form 4
filed Nir LivnehVP, General CounselShares withheld for tax-3,4598.35029 Klocal0Form 4
filed Yael BrennerVP QualityOption exercise+5,0005.93030 Klocal11,266Form 4
filed Yael BrennerVP QualityShares withheld for tax-1,3718.36011 Klocal6,266Form 4
filed Yael BrennerVP QualityOption exercise+5,0005.93030 Klocal11,266Form 4

Markets and events: Kamada Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
165,778
2.58 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-12-08 11:55 UTC, code T3, resumed 12:20 UTC

Fails to deliver

  • : 4,458 shares at $8.26
  • : 4,655 shares at $7.58
  • : 66 shares at $7.09
  • : 29 shares at $7.05
  • : 3 shares at $7.27

Kamada Ltd. scorecard#

Passes 10 of the 12 checks that could be worked out: strongest in growth (6 of 6), weakest in profitability (3 of 5). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
  • Growth6 of 6
  • Profitability3 of 5
  • Financial health1 of 1
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Kamada Ltd.'s statements, beside the median of Pharmaceutical.

Kamada Ltd.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin14.5%1.4%
Net margin11.2%-1.9%
Return on equity7.6%-1.5%
Revenue growth, 3 years a year11.7%2.5%
Revenue growth12.1%7.3%
Free cash flow margin8.7%5.8%

5of 7on the Piotroski tests of financial strength

  • Revenue has grown 4 years in a row.

Kamada Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kamada Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue18016114312910413312711410377
Cost of revenue104918783738677737156
Gross profit76705547304850413221
Research and development131514131114139.71216
Selling, general and administrative———1.80.3—————
Selling and marketing181816150.94.5r4.43.6r0.60.5
General and administrative—————109.28.5——
Total costs and expenses—————0.10.0———
Operating income2620104.5−0.71923197.4−5.5
Interest and finance income1.92.10.60.10.31.01.10.8r0.50.5
Interest expense and finance costs0.90.71.30.90.3r0.30.30.2r0.1r0.1
Income before tax23138.4−2.3−1.91923207.2−5.0
Income tax3.3−1.10.10.10.31.40.7−2.00.31.7
Net income including minority interests20148.3−2.3−2.21722226.9−6.7
Net income attributable to shareholders—148.3−2.3——————
Earnings per share, basic0.350.250.17-0.05-0.050.390.550.550.18-0.18
Earnings per share, diluted0.350.250.15-0.05-0.050.380.550.550.18-0.18
Shares, weighted average (basic)58574945454440403836
Shares, weighted average (diluted)58585445454541403836
Balance sheet
Cash and cash equivalents75785634197043181310.0
Short-term investments—————3931———
Receivables27222027352223283120
Inventory85798869674243292126
Other current assets0.00.00.10.00.00.2————
Current assets1931841701391301781441119777
Property, plant and equipment41362826262625252523
Right-of-use (leased) assets8.99.67.82.63.13.44.04.2——
Goodwill303030r147——————
Other intangible assets————1541.5————
Non-current assets1861881851831893330272523
Total assets379372355322319211174138122100
Accounts payable232825r7.67.17.5r25171816
Debt due within a year———4.42.60.20.50.5r0.60.4
Current liabilities47495076540.233242927
Long-term debt———17200.30.70.7r2.01.8
Lease liabilities (non-current)9.49.47.4———————
Non-current liabilities62636171887.15.72.23.25.7
Retained earnings−17−26−40−48−46−44−61−83−105−111
Total equity2692592441761771791351128967
Total liabilities and equity379372355322319211174138122100
Shares outstanding58585745454540404036
Cash-flow statement
Depreciation and amortization151413125.64.94.53.73.53.5
Share-based compensation0.80.91.31.20.51.01.20.90.51.1
Cash from operating activities25484.329−8.81928113.61.9
Capital expenditure−9.8−11−5.9−3.8−3.7−5.5−2.3−2.9−4.2−2.6
Intangible assets bought————−0.5—————
Cash from investing activities−9.8−11−5.8−3.8−61−13−0.6−5.2−161.6
Debt issued————20———0.31.7
Debt repaid——−17−2.6−0.2−0.5−0.5−0.5r−0.4r−0.2
Dividends paid−12—————————
Cash from financing activities−18−1423−9.31923−1.5−0.6151.5
Exchange-rate effect on cash−0.3−0.20.20.2−0.3−1.8−0.90.6−0.6−0.1
Change in cash−3.0232116−5228255.42.74.9
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2025

What Kamada Ltd. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Proprietary Products$156 M87%
  • Distribution$24 M13%

Countries and regions

  • U.S.A$100 M55%
  • 🇮🇱 Israel$30 M16%
  • Latin America$24 M13%
  • 🇨🇦 Canada$11 M6.0%
  • Europe$9 M5.2%
  • Asia$7 M3.7%
  • Others$0 M0.0%

As of Dec 31, 2025

Where Kamada Ltd. operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Kamada Ltd.: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters1 office1 subsidiary$30 M16%
🇺🇸 USA2 subsidiaries—
🇮🇪 Ireland1 subsidiary—
🇨🇦 Canada$11 M6.0%

How Kamada Ltd. compares in Pharmaceutical

  • Market cap$463 M · higher than 34% of 395
  • Revenue$180 M · higher than 30% of 329
  • Net margin11.2% · higher than 61% of 315
  • Revenue growth12.1% · higher than 65% of 112
  • P/E ratio22.9× · lower than 51% of 174
  • Price / sales2.6× · lower than 47% of 220
  • Price / book1.7× · lower than 61% of 208
  • FCF yield3.4% · higher than 51% of 71

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Kamada Ltd.🇮🇱$463 M22.9×11.2%+12.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kamada Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kamada Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kamada Ltd.? Suggest a correction